COSM News & Events

Cosmos Health announced the planned Q2 U.S. market launch of Cur18b, a next-generation curcumin supplement. Cur18b "enters the U.S. curcumin category as a science-driven alternative to conventional curcumin formulations, addressing one of the most fundamental limitations of the category: poor bioavailability. Based on published pharmacokinetic research, the formulation technology behind Cur18b has demonstrated significantly enhanced absorption, including up to 39C higher free curcumin bioavailability versus standard 95% curcuminoid extracts under study conditions," the company stated.

Reports FY25 revenue $65.3M vs. $54.3M last year. Greg Siokas, CEO, stated: "2025 was the year Cosmos Health proved its model. Not with promises - with numbers. We delivered $65.3M in revenue - a new all-time record, up 20% year-over-year. More importantly, our gross profit nearly doubled, growing 83% to $7.9 million, while gross margin expanded 418 basis points to 12.1%. Our Adjusted EPS improved by 82%, from ($0.65) to ($0.12). These are not incremental improvements. This is the structural transformation of a healthcare platform that has been methodically built over the past several years to be vertically integrated, globally diversified, and increasingly high-margin. At Cana Laboratories, we secured long-term contract manufacturing agreements representing over 12 million units - providing meaningful revenue visibility and a platform for continued margin expansion. Sky Premium Life secured over 300,000 units in new purchase orders globally, with 60 new SKUs introduced, bringing our total portfolio to over 150 products. We also delivered record distribution volumes at CosmoFarm, driven by an expanded pharmacy network, and we entered the United States - the world's largest nutraceuticals market - with locally manufactured, clinically validated products. NOOR Collagen is already generating sales with a clear path to over $12M in annualized revenue at approximately 75% gross margins. We made bold strategic moves. We activated a $300M digital asset facility and initiated an Ethereum treasury strategy. We secured buy-out rights and exclusive licensing for two patented anticancer drugs valued at over $24.5 million, targeting prostate, ovarian, and colorectal cancers. We advanced multiple AI-driven patent filings through Cloudscreen, our proprietary drug repurposing platform, targeting multiple sclerosis, gliomas and hematologic malignancies, as well as allergic inflammation. We ended the year with $3.5M in cash, more than ten times our year-end 2024 cash position. We also own real estate assets with a fair market value that we believe exceeds our current market capitalization, and we are actively evaluating strategic options to unlock that value for our shareholders. I personally increased my ownership by over 3.3 million shares in 2025. I do not do that as a formality. I do that because I believe - with full conviction - that the intrinsic value of Cosmos Health is a significant multiple of where this stock trades today. Our revenue is at a record. Our margins are expanding. Our U.S. business is ramping. Our pipeline is advancing. And we have only just begun to realize the potential of this platform. 2026 has started with strong momentum across all divisions, and we will provide updated guidance in the near term. To our shareholders: we hear you. We are executing for you. And the best chapters of this story are still ahead."

Cosmos Health confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track. Greg Siokas, CEO of Cosmos Health, stated: "Our business has never been stronger. Q3 2025 marked our highest revenue, gross profit, and gross margin in the Company's history - and that momentum has continued. Our geographically diversified platform insulates us from regional disruptions, while the accelerating U.S. expansion of Sky Premium Life NOOR represents a transformational growth opportunity. We expect NOOR U.S. revenues to exceed $12 million within the next 12 months, at gross margins of approximately 75%, and we look forward to providing the full picture with our forthcoming 10-K filing."

Cosmos Health announced the planned Q2 U.S. launch of Liv18, a next-generation liver health supplement powered by BergacynFF, a patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials. Liv18 is expected to launch in Q2 across multiple distribution channels in the United States, including e-commerce platforms, health and specialty retail outlets, and healthcare practitioner channels, supported by targeted consumer awareness and outreach initiatives.